The Prevalence of Metabolically associated Steatotic Liver Disease in Patients with Inflammatory Bowel Disease in Erbil City
DOI:
https://doi.org/10.56056/Keywords:
Inflammatory bowel disease, Non-alcoholic fatty liver diseaseAbstract
Background and Objective: The non-alcoholic fatty liver disease is prevalent in about one-fourth of the world population. The link between inflammatory bowel diseases and non-alcoholic fatty liver disease has been of great concern in last decades. This study aimed to determine the prevalence of non-alcoholic fatty liver disease in patients with inflammatory bowel disease.
Methods: A descriptive cross-sectional study was conducted in Hawler Gastroenterology and Hepatology center at Rzgari teaching hospital in Erbil city-Kurdistan region/Iraq in duration of twelve months (5th of April 2023 to 5th of April 2024) on a sample of one hundred patients with inflammatory bowel disease. The prevalence of non-alcoholic fatty liver disease and factors associated with it (past medical history, platelets, C-reactive protein, fasting blood sugar, Hemoglobin A1c…etc) were studied.
Results: The prevalence of non-alcoholic fatty liver disease was (24%) with fibrosis scores of F0-F2 and predominant grading of grade I (23%); in contrast grade II was reported in one inflammatory bowel disease patient only. Past medical history of hypertension diabetes mellitus and dyslipidemia was a significant risk factor of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. Abnormal results of fasting blood glucose, HemoglobinA1c, triglyceride, High-density-lipoprotein, Aspartate-transaminase and Alanine-transaminase levels of inflammatory bowel disease patients were significantly related to non-alcoholic fatty liver disease.
Conclusion: The prevalence of non-alcoholic fatty liver disease in patients with inflammatory bowel disease is close to prevalence of non-alcoholic fatty liver disease in general population.
Downloads
References
1. Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract 2022; 28(5):528-562.
2. Younossi ZM, Stepanova M, Younossi Y, Golabi P, Mishra A, Rafiq N, et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut 2020; 69(3):564-568.
3. Le MH, Le DM, Baez TC, Wu Y, Ito T, Lee EY, et al. Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons. J Hepatol 2023; 79(2):287-295.
4. Younossi ZM, Koenig AB, Abdelatif D. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64:73–84.
5. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 2023; 77(4):1335-1347.
6. Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 2020; 69(9):1691-1705.
7. Huang S, Bao Y, Zhang N, Niu R, Tian L. Long-term outcomes in lean and non-lean NAFLD patients: a systematic review and meta-analysis. Endocrine. 2024 Jul;85(1):134-141. doi: 10.1007/s12020-023-03351-5/
8. Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol 2018; 53(3):305-353.
9. Barberio B, Zamani M, Black CJ, Savarino EV, Ford AC. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2021; 6(5):359-370.
10. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017; 390(10114):2769-2778.
11. Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis 2015; 21(8):1982-1992.
12. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016; 65(8):1038-1048.
13. Schuster S, Cabrera D, Arrese M, Feldstein AE. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol 2018; 15(6):349-364.
14. Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology 2020; 158(7):1999-2014.e1.
15. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol 2024; 29(1):101133.
16. Bellinato F, Gisondi P, Mantovani A, Girolomoni G, Targher G. Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies. J Endocrinol Invest 2022; 45(7):1277-1288.
17. Lin A, Roth H, Anyane-Yeboa A, Rubin DT, Paul S. Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis 2021; 27(6):947-955.
18. Dias E, Andrade P, Lopes S, Gonçalves R, Cardoso P, Gaspar R, et al. Liver biopsy in inflammatory bowel disease patients with sustained abnormal liver function tests: a retrospective single-center study. Ann Gastroenterol 2023; 36(1):54-60.
19. Lindén D, Romeo S. Therapeutic opportunities for the treatment of NASH with genetically validated targets. J Hepatol 2023; 79(4):1056-1064.
20. Dolce A, Della Torre S. Sex, Nutrition, and NAFLD: Relevance of Environmental Pollution. Nutrients 2023; 15(10):2335.
21. Michielan A, D'Incà R. Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut. Mediators Inflamm 2015; 2015:628157.
22. Zou ZY, Shen B, Fan JG. Systematic Review with Meta-analysis: Epidemiology of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2019; 25(11):1764-1772.
23. Nasir K, Acquah I, Dey AK, Agrawal T, Hassan SZ, Glassner K, et al. Inflammatory bowel disease and atherosclerotic cardiovascular disease in U.S. adults-A population-level analysis in the national health interview survey. Am J Prev Cardiol 2022; 9:100316.
24. Gizard E, Ford AC, Bronowicki J-P, Peyrin-Biroulet L. Systematic review: the epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. Aliment Pharmacol Ther.2014; 1: 3–15.
25. Bessissow T, Le NH, Rollet K, Afif W, Bitton A, Sebastiani G. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2016; 22(8):1937-1944.
26. Goel A, Campos A, Molinari A. Diffuse hepatic steatosis (grading). Reference article, Radiopaedia.org Available from: https://doi.org/10.53347/rID-33279/
27. Maresca R, Mignini I, Varca S, Calvez V, Termite F, Esposto G, et al. Inflammatory Bowel Diseases and Non-Alcoholic Fatty Liver Disease: Piecing a Complex Puzzle Together. Int J Mol Sci 2024; 25(6):3278.
28. Abenavoli L, Spagnuolo R, Scarlata GGM, Scarpellini E, Boccuto L, Luzza F. Ultrasound Prevalence and Clinical Features of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Real-Life Cross-Sectional Study. Medicina (Kaunas) 2023; 59(11):1935.
29. Abusaib M, Ahmed M, Nwayyir HA, Alidrisi HA, Al-Abbood M, Al-Bayati A, et al. Iraqi Experts Consensus on the Management of Type 2 Diabetes/Prediabetes in Adults. Clin Med Insights Endocrinol Diabetes 2020; 13:1179551420942232.
30. Hoffmann P, Jung V, Behnisch R, Gauss A. Prevalence and risk factors of nonalcoholic fatty liver disease in patients with inflammatory bowel diseases: A cross-sectional and longitudinal analysis. World J Gastroenterol 2020; 26(46):7367-7381.
31. Stoleru G, Abutaleb A, Cross RK, Shetty K, Sakiani S, et al. Nonalcoholic Fatty Liver Disease Is Common in IBD Patients However Progression to Hepatic Fibrosis by Noninvasive Markers Is Rare. Dig Dis Sci 2020; 66: 3186–3191.
32. Martínez-Domínguez SJ, García-Mateo S, Laredo V, Gargallo-Puyuelo CJ, Gallego Llera B, López de la Cruz J, et al. Liver Fibrosis in Non-Alcoholic Fatty Liver Disease and Progression to Hepatocellular Carcinoma in Patients with Inflammatory Bowel Disease: A Systematic Review. Cancers (Basel) 2023; 15(13):3367.
33. Sourianarayanane A, Garg G, Smith TH, Butt MI, McCullough AJ, Shen B. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. J Crohns Colitis 2013; 7(8): e279-285.
34. Capela TL, Silva VM, Freitas M, Arieira C, Gonçalves TC, de Castro FD, et al. Identifying inflammatory bowel disease patients at risk of metabolic dysfunction-associated fatty liver disease: usefulness of non-invasive steatosis predictive scores. BMC Gastroenterol 2023; 23(1):437.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Rieber Abdulrahman Kareem, Abdullah Saeed Ibrahim, Altun Mahmud Saleh
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The copyright on any article published in AMJ (The Scientific Journal of Kurdistan Higher Council of Medical Specialties )is retained by the author(s) in agreement with the Creative Commons Attribution Non-Commercial ShareAlike License (CC BY-NC-SA 4.0)
